Avances en el tratamiento del cáncer de tiroides
Resumen
La doctora Sarimar Agosto-Salgado con su tema “Avances en el tratamiento del cáncer de tiroides”, aborda los inicios del tratamiento con las primeras terapias aprobadas para el cáncer de tiroides refractario a yodo radioactivo, hasta llegar a las terapias dirigidas a la mutación BRAF V600E, y a los enfoques adicionales de utilidad en los casos de cáncer de tiroides agresivo: la rediferenciación y la intervención neoadyuvante.
Descargas
Referencias bibliográficas
Lim H, Devesa SS, Sosa JA, Check D, Kitahara CM. Trends in thyroid cancer incidence and mortality in the united states, 1974-2013. JAMA 2017;317:1338-1348. https://doi.org/10.1001/jama.2017.2719.
Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med 2015;372:621-630. https://doi.org/10.1056/NEJMoa1406470.
Brose MS, Nutting CM, Jarzab B, Elisei R, Siena S, Bastholt L, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet 2014;384:319-328. https://doi.org/10.1016/s0140-6736(14)60421-9.
Brose MS, Robinson BG, Sherman SI, Jarzab B, Lin CC, Vaisman F, et al. Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC-311 trial. Cancer 2022;128:4203-4212. https://doi.org/10.1002/cncr.34493.
Brose MS, Worden FP, Newbold KL, Guo M, Hurria A. Effect of age on the efficacy and safety of lenvatinib in radioiodine-refractory differentiated thyroid cancer in the phase III SELECT trial. J Clin Oncol 2017;35:2692-2699. https://doi.org/10.1200/jco.2016.71.6472.
Subbiah V, Kreitman RJ, Wainberg ZA, Cho JY, Schellens JHM, Soria JC, et al. Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study. Ann Oncol 2022;33:406-415. https://doi.org/10.1016/j.annonc.2021.12.014.
Subbiah V, Hu MI, Wirth LJ, Schuler M, Mansfield AS, Curigliano G, et al. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study. Lancet Diabetes Endocrinol 2021;9:491-501. https://doi.org/10.1016/s2213-8587(21)00120-0.
Waguespack SG, Drilon A, Lin JJ, Brose MS, McDermott R, Almubarak M, et al. Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma. Eur J Endocrinol 2022;186:631-643. https://doi.org/10.1530/eje-21-1259.
Rothenberg SM, McFadden DG, Palmer EL, Daniels GH, Wirth LJ. Redifferentiation of iodine-refractory BRAF V600E-mutant metastatic papillary thyroid cancer with dabrafenib. Clin Cancer Res 2015;21:1028-1035. https://doi.org/10.1158/1078-0432.Ccr-14-2915.
Lamartina L, Anizan N, Dupuy C, Leboulleux S, Schlumberger M. Redifferentiation-facilitated radioiodine therapy in thyroid cancer. Endocr Relat Cancer 2021;28:T179-t191. https://doi.org/10.1530/erc-21-0024.
Contrera KJ, Gule-Monroe MK, Hu MI, Cabanillas ME, Busaidy NL, Dadu R, et al. Neoadjuvant selective RET inhibitor for medullary thyroid cancer: A case series. Thyroid 2023;33:129-132. https://doi.org/10.1089/thy.2022.0506.
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.
Métricas
